Market Potential
Transpire Bio is a US-based, clinical-stage, revenue-generating, biopharmaceutical company with proprietary inhalation formulation and delivery platforms that unlock new therapeutic opportunities, maximizing value while uniquely reducing investment risk.
The problem we solve
Oral drug delivery—the most common route for new therapies—often presents challenges for patients such as adverse events, poor bioavailability, drug-drug interactions, and food effects. Inhalation offers a compelling alternative, helping to overcome these limitations while unlocking novel therapeutic approaches and new economic opportunities.
Explore the science behind inhalation’s advantages
Our solution
We are experts in inhalation technology. Our clinical-stage, revenue-generating formulation and delivery platforms are customizable to different clinical needs, enabling the development of new therapies designed to improve effectiveness or tolerability.
Discover how our customizable inhalation platforms unlock new therapeutic opportunities
Opportunity
Our unique inhalation technologies and capabilities enable multiple commercialization and revenue-generation options, increasing our opportunity for success and growth.
We are focused on three strategic areas targeting multi-billion-dollar opportunities.
Click on each area below to learn more:
Innovative
biopharmaceuticals
We are actively advancing multiple assets targeting attractive, multi-billion-dollar opportunities in:
We are actively advancing multiple assets targeting attractive, multi-billion-dollar opportunities in:
Clinical Area
Target US Addressable Market
Status
Interstitial Lung Disease (ILDs) - Multiple Assets
~$28 billion
Clinical
Central Nervous System (CNS)
~$29 billion
Phase 1 Clinical Study Starting in 2025
Oncology
~$10 billion
Phase 1 Clinical Study Starting in 2025
Obesity & Diabetes
~$1.8 trillion
Preclinical
Future Applications
Our fully-developed CBD formulation platform has multiple clinical applications, including other CNS disorders and oncology applications.
Explore our pipeline of next-generation therapies
Co-development
partnerships
Strategic pharma partnerships to rapidly advance innovative inhaled therapies.
Strategic pharma partnerships to rapidly advance innovative inhaled therapies.
- Strategic partnership established, targeting the multi-billion-dollar lung disease market
- Eight-figure partnership revenues have been generated to-date
- Actively pursuing additional partnership opportunities
- Validates technology and funds innovative portfolio investments
See how we help our partners innovate
Complex Generics
Development of early-entry, difficult-to-replicate asthma/COPD generic inhaled therapies.
Development of early-entry, difficult-to-replicate asthma/COPD generic inhaled therapies.
- Targeting two large respiratory markets valued together at over $13 billion globally
- Attractive opportunity due to significant barriers to entry and lucrative margins
- In advanced development, with commercialization partnerships being pursued
- Validates technology and funds innovative portfolio investments
Learn about our capabilities that enable inhalation innovation
Innovative
biopharmaceuticals
We are actively advancing multiple assets targeting attractive, multi-billion-dollar opportunities in:
We are actively advancing multiple assets targeting attractive, multi-billion-dollar opportunities in:
Clinical Area
Target US Addressable Market
Status
Interstitial Lung Disease (ILDs) - Multiple Assets
~$28 billion
Clinical
Central Nervous System (CNS)
~$29 billion
Phase 1 Clinical Study Starting in 2025
Oncology
~$10 billion
Phase 1 Clinical Study Starting in 2025
Obesity & Diabetes
~$1.8 trillion
Preclinical
Future Applications
Our fully-developed CBD formulation platform has multiple clinical applications, including other CNS disorders and oncology applications.
Explore our pipeline of next-generation therapies
Co-development
partnerships
Strategic pharma partnerships to rapidly advance innovative inhaled therapies.
Strategic pharma partnerships to rapidly advance innovative inhaled therapies.
- Strategic partnership established, targeting the multi-billion-dollar lung disease market
- Eight-figure partnership revenues have been generated to-date
- Actively pursuing additional partnership opportunities
- Validates technology and funds innovative portfolio investments
See how we help our partners innovate
Complex Generics
Development of early-entry, difficult-to-replicate asthma/COPD generic inhaled therapies.
Development of early-entry, difficult-to-replicate asthma/COPD generic inhaled therapies.
- Targeting two large respiratory markets valued together at over $13 billion globally
- Attractive opportunity due to significant barriers to entry and lucrative margins
- In advanced development, with commercialization partnerships being pursued
- Validates technology and funds innovative portfolio investments
